Merus N.V.’s Post

We’re excited to announce that for a second time in a row, based on positive survey results from our employees, we have been awarded a “World-class Workplace” for 2024-2025 by Effectory! We are grateful for everyone that makes Merus as a great place to work! #CloseInOnCancer

We’re excited to announce that the first patient has been dosed in LiGeR-HN2, a phase 3 trial evaluating petosemtamab in 2/3L r/m #HNSCC #CloseInOnCancer https://lnkd.in/gKEipjHp

Check out Benjamin’s story and learn how Merus is a place where he can focus on helping give patients a better quality of life. It’s an environment where curiosity and eagerness to innovate are very strong. Read more>> https://lnkd.in/eHh2WK7F #CloseInOnCancer #JoinTheMerusMission

Join us at the forefront of innovation. The stakes are high, and so are our ambitions. There is exciting work to be done with colleagues worldwide. Envision being part of our mission to #CloseInOnCancer by checking our open positions.  https://careers.merus.nl/ #JoinTheMerusMission

NRG1 gene fusions have been identified across many tumor types and generally occur in the absence of other driver mutations. Learn more at https://bit.ly/45NptDs. #PrecisionOncology #FindTheFusions #PrecisionMedicine

Our team members are the heart and soul of Merus. We’ve invited our colleagues to share what makes Merus a great place to work. We’re kicking off our series with Maaike, our Associate Director Quality Systems. #CloseInOnCancer #JoinTheMerusMission Read more>> https://lnkd.in/eNz3svzA

Every day, we’re moving ahead in our mission to #CloseInOnCancer. We’re up to the challenge and unwavering in our determination. In the coming weeks, we’ll introduce you to some of our team members, who’ll share what motivates them and sparks their passion to make a difference. https://merus.nl/

At Merus, we work towards discovering and developing new treatments for cancer. Every day, we bring a sense of urgency and a passion to help patients with #HNSCC, #NSCLC, #PDAC, and other types of cancer. Time is of the essence. #CloseInOnCancer https://merus.nl/

Merus announces first patient dosed in phase 2 trial of petosemtamab in 2L CRC.  #CloseInOnCancer https://lnkd.in/eNzJp6Dc

Welcoming Dr. Fabian Zohren as our new Chief Medical Officer. Bringing late-stage clinical development expertise to our team, Dr. Zohren will play a key role in the initiation of our two randomized phase 3 trials, planned to start later this year. #CloseInOnCancer